Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
20 September 2019 | Story Rulanzen Martin | Photo Charl Devenish
Kovsies Multilingual Mokete
The Multilingual Mokete embodies the ideals of the university to become inclusive, while promoting a multicultural environment.

The first Kovsies Multilingual Mokete was a celebration of language and culture; it is a commitment by the University of the Free State (UFS) to nurture an attitude of inclusiveness and acceptance on all three of its campuses. Hosted on the Bloemfontein Campus on Wednesday 18 September 2019, the mokete was a hype of activity with drama, poetry, music, dance, and scrumptious cultural cuisine.

“This initiative was coordinated to promote and celebrate all our regional languages, but also important – our regional cultures.” This was the words of Prof Francis Petersen, Rector and Vice-Chancellor of the UFS, on opening the first Kovsies Multilingual Mokete.

The Mokete stage came alive with the impeccable voices of our students and staff as they personified multilingualism through the spoken word in the form of poems, the drama production, Dogg’s Hamlet in the Scaena, praise songs, and dance. A mural featuring individual artworks was also on display during the mokete, as well as a screening of the movie, The Visitor.

The Mokete was concluded by Simple Stories, a band of former Kovsie students, with Early B as the main act.  The People’s Choice Award winner of the day was Soetbravado, winners of the UFS SingOff competition.

“I think the inaugural Multilanguage festival is full of potential. Tolerance and understanding of different cultures are what I see here. I think it’s amazing and I would recommend the UFS to continue with it,” says Jon-Dylon Petersen, former SRC member and final-year Quantity Surveying and Construction Management student. 

Kovsies First Multilingual Mokete
The traditional outfits made for a colourful Mokete. Photo:Charl Devenish

Mokete part of UFS project to foster sense of belonging


The mokete is furthermore presented in support of the Integrated Transformation Plan (ITP) work streams on Teaching and Learning, Student and Staff Experience, and the Multi-Campus Model. “As a university, we are proud of the many languages and cultures which form part of this university. It creates a level of diversity and it is through diversity that we can build strength within the university,” says Prof Petersen. 

This initiative of multilingualism is part of the university’s language policy, which promotes a sense of belonging and acceptance among people. “We want to create opportunities and platforms and campuses where everyone should feel welcome, and to create the ability for each culture and language group to also learn from one another.”

The ultimate goal is to use the multilingual initiatives to prepare our students for the multilingual and multicultural world, but also to stay connected to our own heritage and background. 

Dogg's Hamlet
The play Dogg's Hamlet was showcased in the Scaena Theatre during the Mokete. Photo: Charl Devenish

Mokete should become an annual event 


The reaction to the mokete was overwhelmingly positive and it was well received in the Kovsie community. “It’s a beautiful experience to see how academics can come to a university and showcase not only different languages, but different cultures; it’s something which should continue in the spirit of ubuntu and diversity, and can maybe become a national festival,” says Almondreaux Williams, third-year LLB student.

Not only was the mokete a celebration of multilingualism at the UFS; it was also a platform to express different cultures in the form of traditional attire.

''It’s getting people together. All of us, all the cultural groups are here together. The performances were awesome,” says Sibongile Witbooi, a third-year Geology student and Residence Committee member for Culture at Akasia residence. 

Multilingual Mokete
Authentic South African cuisine was on the menu for the day. Moketers could enjoy array of flavours from bobotie and rice to
chesanyama and pap. Photo: Charl Devenish


News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept